Jpmorgan Chase & CO Allakos Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Allakos Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,610 shares of ALLK stock, worth $450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,610
Previous 1,617
0.43%
Holding current value
$450
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ALLK
# of Institutions
79Shares Held
68.8MCall Options Held
20.9KPut Options Held
0-
Bvf Inc San Francisco, CA16.6MShares$4.63 Million0.75% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$1.72 Million0.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.7MShares$1.6 Million0.3% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.63MShares$1.02 Million1.7% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.59MShares$1.01 Million0.01% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $23.7M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...